Techcyte, a leading provider of AI-powered digital diagnostics for anatomic and clinical pathology, today announced that its Research Use Only  (RUO) platform, Techcyte Fusion™, now includes Mindpeak GmbH as a partner in the Fusion™ Partner Program. This collaboration brings  together two leaders in AI-driven pathology with a shared mission: to improve diagnostic accuracy, efficiency, and reproducibility in cancer  diagnostics.

Founded in 2018 and based in Hamburg, Germany, Mindpeak is a pioneer in deploying AI solutions for routine diagnostics in the US and EU. Their suite of “0-clickˮ AI tools—including RUO use of IHC analysis tools for markers like HER2, Ki‑67, ER/PR and PD‑L1, alongside H&E‑based  algorithms for breast and prostate cancer research, with no manual configuration required. Mindpeakʼs proprietary hybrid deep learning technique  and “IHC-firstˮ foundation model underpin their ability to support a range of laboratory workflows with minimal setup, acknowledging variations  in slide preparation and staining.

By integrating Mindpeakʼs breast, prostate, and additional AI solutions into the Techcyte Fusion platform, users will benefit from expanded access  to cutting-edge algorithms that offer tools that may assist with routine analytical processes, such as cell detection and biomarker quantification, intended to support reproducible research workflows. The addition of Mindpeakʼs RUO algorithms enhances the Fusion platformʼs ability to  support laboratories seeking scalable, interoperable AI solutions.

“We believe the future of pathology depends on the widespread adoption of workflow-based, AI-enabled digital pathology,ˮ said Matt Smith, Chief  Strategy Officer at Techcyte. “Without it, labs will struggle to meet growing demand, manage complexity, and operate efficiently. By partnering with  innovators like Mindpeak, we are supporting a future vision in which AI‑enabled workflows play an increasingly prominent role in research- oriented digital pathology.ˮ

“We built Mindpeak to support pathologists with reliable AI that fits effortlessly into daily workflows,ˮ said Felix Faber, Founder and CEO of  Mindpeak. “Partnering with Techcyte allows us to reach more labs with a shared commitment to transforming cancer diagnostics through high- quality, scalable solutions.ˮ

This partnership underscores the ongoing evolution of digital pathology, where seamless integration, validated AI, and user-centric design are key  to accelerating adoption and improving patient care.

For more information about the Techcyte Fusion Partner Program, visit www.techcyte.com.

About Techcyte

Techcyte is transforming the practice of pathology through a unified, AI-powered digital platform that streamlines complex workflows, integrates  with core lab systems, and enhances communication across the lab.

By partnering with leading laboratories, scanner manufacturers, diagnostic hardware providers, and AI developers, we deliver a unified digital  pathology platform to labs and clinics around the world, furthering our mission to positively impact the health of humans, animals, and the environment.

Techcyteʼs anatomic and clinical pathology platform is for Research Use Only in the United States.

About Mindpeak

Mindpeak is the leading company in AI-powered digital pathology, bridging the gap from biomarker development to clinical diagnostics. Founded  in 2018, Mindpeakʼs AI technology enables laboratories to extract actionable insights from H&E, IHC and mIF tissue images – ranging from subcellular biomarker quantification to predictive patient stratification. The solutions support both routine diagnostics and the translation of novel biomarkers into real-world clinical applications.